Acoramidis not checked

Eidos Therapeutics, a BridgeBio company · AG10 · ALXN 2060

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
12 in total · 5 in the EU
Targets
 

What this is

How it works
Transthyretin Stabilizer FDA class
How it’s given
“Study drug is defined as acoramidis 712 mg (equivalent to 800 mg acoramidis hydrochloride) taken orally twice daily for 36 months of open label treatment.”In the company’s words, NCT07695701 on ClinicalTrials.gov
Tested for
Amyloidosis (3 trials), Amyloid Cardiomyopathy (3 trials), Transthyretin Amyloidosis (2 trials), Amyloid Cardiomyopathy, Transthyretin-Related (2 trials), Cardiomyopathies (2 trials), Polyneuropathies (2 trials), Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Heart Diseases and 5 more
Main trialPhase 4
“The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.”In the company’s words, NCT07695701 on ClinicalTrials.gov
Other names
AG10 · ALXN 2060 · Eidos Therapeutics AG10

Other drugs for Amyloidosis

All 23 drugs for Amyloidosis

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Aug 2030 Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Phase 3Active, not recruiting 15 Apr 2028 Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Phase 3Recruiting Oct 2031 Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Phase 3Not yet recruiting Nov 2037 To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Phase 3Completed 11 May 2023 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Phase 3Withdrawn 31 Mar 2024 Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy
Phase 3Withdrawn Sep 2026 Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)
Phase 2Completed 5 Oct 2018 Study of AG10 in Amyloid Cardiomyopathy
Phase 2Terminated 15 Sep 2025 Open-Label Study of AG10 in Patients With Cardiomyopathy
Phase 1Completed 5 Feb 2018 Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
Phase 1Completed 4 Aug 2021 A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects
Phase 4Authorised not given Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Acoramidis

Following is part of Solo: you see every change to Acoramidis the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in